Clinical Trials Browser

Phase 2 × OTHER × Crizotinib × Clear all

NCT04030429 2025-07-16

Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

Phase 2 Terminated

Endometrial Cancer Recurrent

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Phase 2 Recruiting

Rare Tumor

NCT06563999 2024-12-10

NUMER

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04084717 2024-07-16

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04322578 2024-06-04

CONFIRM

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT02223819 2023-12-06

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

Phase 2 Completed

34 enrolled 9 charts

Uveal Melanoma

NCT02419287 2023-03-06

Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

Phase 2 Completed

Lymphoma, Large-Cell, Anaplastic

NCT05725200 2023-02-21

EVIDENT

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03574402 2022-12-06

TRUMP

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02612194 2022-11-03

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Phase 2 Terminated

8 enrolled 16 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT02183870 2022-06-16

EUCROSS

Phase 2 Completed

Adenocarcinoma, Lung Neoplasms

NCT03088930 2022-02-11

Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer

Phase 2 Completed

3 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung

NCT02638428 2020-03-19

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Phase 2 Unknown

Other solid neoplasm

Relapsed Pediatric Solid Tumor

NCT02142036 2019-03-13

MetAction

Phase 2 Completed

Neoplasm Metastasis

NCT02836847 2018-05-07

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Phase 2 Unknown

Gastrointestinal

Gallbladder Neoplasms

NCT02499614 2017-10-25

METROS

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02946359 2016-11-02

A+C in Metastatic Lung Adenocarcinoma Cancer

Phase 2 Unknown

Lung Adenocarcinoma Metastatic